Kuros Biosciences Conducts Productive Annual General Meeting
Kuros Biosciences (“Kuros”), a frontrunner in bone healing technologies, successfully convened its Annual General Meeting to discuss significant matters concerning the company.
Key Resolutions Approved by Shareholders
During the meeting, vital resolutions were approved including the acceptance of the Annual Report, Annual Financial Statements, and Consolidated Financial Statements. The shareholders expressed their confidence by granting discharge to the Board and the Executive Committee. Each resolution was met with strong support, ensuring the company is on a clear path moving forward.
Re-election and New Appointments
In a stride towards stability and governance, Clemens van Blitterswijk was re-elected as Chairman, while Joost de Bruijn, Oliver Walker, Albert Arp, and Chris Fair (CEO) continued their roles on the Board. Additionally, Kimberley Elting was elected as a new member, reinforcing the diverse expertise of the Board.
Independent Proxies and Auditors Retained
In maintaining transparency and accountability, the law firm Keller AG from Zurich was re-elected as the independent Proxy. Furthermore, PricewaterhouseCoopers Ltd will return to serve as Kuros's auditor for another year, ensuring a thorough examination of the company’s financial affairs.
Approved Incentive Plan and Capital Adjustments
An exciting aspect of the AGM was the approval of the U.S. Option and Equity Incentive Plan Regulation for 2025. This regulation aims to attract and retain top talent, driving the company’s vision to revolutionize bone healing. Additionally, the meeting included amendments to the Articles of Association, specifically increasing the Conditional Share Capital for Employees, Directors, and those in Comparable Positions, showcasing a commitment to its workforce.
Summary of Shareholder Participation
The gathering witnessed impressive shareholder participation, with 19,610,174 shares represented, equating to 51.8% of the total 37,868,889 shares. This strong turnout reflects the stakeholders’ confidence in Kuros Biosciences and its future prospects.
Contact Information for Inquiries
For any further information regarding the Annual General Meeting or company matters, please reach out to:
Alexandre Müller, Investor Relations
Tel: +41 43 268 32 31
IR@kurosbio.com
Daniel Geiger, Chief Financial Officer
Tel: +41 44 733 47 41
daniel.geiger@kurosbio.com
About Kuros Biosciences
Kuros Biosciences is dedicated to discovering and delivering innovative biologic technologies, enhancing patient outcomes globally. Known for its flagship product, MagnetOs™, this advanced bone graft technology is already making waves in the orthopedic field across various countries.
MagnetOs™: A Unique Bone Graft Solution
MagnetOs™ stands out in the realm of orthopedic products due to its groundbreaking NeedleGrip™ surface technology, which catalyzes bone growth even in challenging environments. This innovation leverages the body's natural healing mechanisms, providing a dependable option for surgeons aiming to ensure optimal recovery for their patients.
Frequently Asked Questions
What was the primary focus of the Annual General Meeting?
The meeting focused on approving financial statements, resolutions regarding board appointments, and an incentive plan for employees.
Who were re-elected during the meeting?
Clemens van Blitterswijk was re-elected as Chairman, along with other Board members.
What new plans were approved by the shareholders?
The shareholders approved the U.S. Option and Equity Incentive Plan Regulation for 2025, aimed at enhancing talent retention.
What percentage of shares was represented at the AGM?
Approximately 51.8% of the shares were represented at the Annual General Meeting.
How can investors reach the company for more information?
Investors can contact Alexandre Müller for investor relations or Daniel Geiger for financial inquiries through the provided email addresses.
